Development Level

Tbio 502 | 10,625
Tdark 122 | 7,003
Tchem 70 | 1,890
Tclin 11 | 602

Collection

Eligible Kinase Proteins 2 | 134

IMPC Term

preweaning lethality, complete... 48 | 633
embryonic lethality prior to t... 18 | 187
decreased total body fat amoun... 15 | 186
abnormal behavior 13 | 226
decreased lean body mass 12 | 195
embryonic lethality prior to o... 12 | 148
increased or absent threshold ... 12 | 128
decreased circulating choleste... 11 | 85
preweaning lethality, incomple... 11 | 260
abnormal embryo size 10 | 112
decreased body weight 10 | 174
increased circulating alkaline... 10 | 119
abnormal lens morphology 9 | 73
decreased bone mineral content 9 | 157
decreased circulating HDL chol... 9 | 77
decreased circulating LDL chol... 9 | 37
decreased grip strength 9 | 123
increased mean corpuscular vol... 9 | 91
decreased circulating alanine ... 8 | 53
decreased circulating triglyce... 8 | 83
increased bone mineral content 8 | 92
increased hematocrit 8 | 36
abnormal bone structure 7 | 131
abnormal sleep behavior 7 | 63
cardiovascular system phenotyp... 7 | 35
decreased body length 7 | 108
decreased bone mineral density 7 | 126
decreased circulating glucose ... 7 | 121
decreased circulating serum al... 7 | 79
enlarged heart 7 | 111
increased mean corpuscular hem... 7 | 93
decreased caudal vertebrae num... 6 | 49
hyperactivity 6 | 108
increased grip strength 6 | 83
increased lean body mass 6 | 107
decreased circulating free fat... 5 | 39
decreased circulating insulin ... 5 | 75
decreased fasted circulating g... 5 | 49
decreased leukocyte cell numbe... 5 | 54
decreased mean corpuscular hem... 5 | 34
decreased mean corpuscular vol... 5 | 50
decreased startle reflex 5 | 48
enlarged spleen 5 | 26
increased circulating HDL chol... 5 | 63
increased circulating choleste... 5 | 53
increased fasted circulating g... 5 | 68
increased hemoglobin content 5 | 45
increased mean corpuscular hem... 5 | 25
abnormal coat/hair pigmentatio... 4 | 54
decreased hematocrit 4 | 25
decreased hemoglobin content 4 | 53
decreased rib number 4 | 59
enlarged lymph nodes 4 | 27
hydrometra 4 | 13
hypoactivity 4 | 89
impaired glucose tolerance 4 | 52
increased body weight 4 | 42
increased bone mineral density 4 | 52
increased circulating LDL chol... 4 | 15
increased erythrocyte cell num... 4 | 26
increased leukocyte cell numbe... 4 | 37
increased sacral vertebrae num... 4 | 62
prenatal lethality prior to he... 4 | 64
abnormal behavioral response t... 3 | 52
abnormal femur morphology 3 | 14
abnormal heart morphology 3 | 51
abnormal hindbrain development 3 | 24
abnormal kidney morphology 3 | 30
abnormal midbrain development 3 | 22
abnormal neural tube closure 3 | 37
abnormal pericardium morpholog... 3 | 11
abnormal retina morphology 3 | 100
abnormal testis morphology 3 | 30
abnormal tooth morphology 3 | 24
decreased CD8-positive, alpha-... 3 | 26
decreased T cell number 3 | 31
decreased circulating aspartat... 3 | 27
decreased circulating total pr... 3 | 41
decreased gamma-delta T cell n... 3 | 18
decreased heart rate 3 | 10
decreased heart rate variabili... 3 | 11
decreased lactate dehydrogenas... 3 | 14
decreased lumbar vertebrae num... 3 | 62
decreased mean corpuscular hem... 3 | 19
decreased total retina thickne... 3 | 20
decreased vertical activity 3 | 22
hydrops fetalis 3 | 22
increased circulating bilirubi... 3 | 16
increased circulating free fat... 3 | 17
increased circulating potassiu... 3 | 31
increased circulating sodium l... 3 | 71
increased startle reflex 3 | 38
limb grasping 3 | 35
male infertility 3 | 62
short tibia 3 | 82
thrombocytopenia 3 | 46
thrombocytosis 3 | 23
increased circulating chloride... 2 | 43
increased total body fat amoun... 2 | 57
small testis 2 | 37

Disease

ovarian cancer 404 | 8,484
osteosarcoma 350 | 7,933
medulloblastoma, large-cell 259 | 6,234
psoriasis 256 | 6,685
glioblastoma 235 | 5,572
atypical teratoid / rhabdoid tumor 198 | 4,369
lung cancer 186 | 4,466
intraductal papillary-mucinous neoplasm (IPMN) 139 | 3,289
intraductal papillary-mucinous adenoma (IPMA) 137 | 2,956
intraductal papillary-mucinous carcinoma (IPMC) 134 | 2,988
invasive ductal carcinoma 130 | 2,950
Breast cancer 129 | 3,094
malignant mesothelioma 128 | 3,162
pilocytic astrocytoma 124 | 3,086
pediatric high grade glioma 119 | 2,712
non-small cell lung cancer 118 | 2,798
lung adenocarcinoma 115 | 2,713
Carcinoma 113 | 2,147
lung carcinoma 110 | 2,844
ependymoma 109 | 2,514
oligodendroglioma 108 | 2,849
primitive neuroectodermal tumor 101 | 3,031
pancreatic cancer 100 | 2,300
subependymal giant cell astrocytoma 96 | 2,287
Pick disease 94 | 1,893
pancreatic ductal adenocarcinoma liver metastasis 94 | 1,795
Multiple myeloma 91 | 1,327
astrocytoma 87 | 1,493
Cancer 85 | 2,346
diabetes mellitus 85 | 1,663
interstitial cystitis 83 | 2,299
acute quadriplegic myopathy 80 | 1,157
group 4 medulloblastoma 79 | 1,875
adult high grade glioma 77 | 2,148
astrocytic glioma 72 | 2,241
ductal carcinoma in situ 72 | 1,745
breast carcinoma 71 | 1,614
juvenile dermatomyositis 71 | 1,189
tuberculosis 67 | 1,557
ulcerative colitis 67 | 2,087
primary pancreatic ductal adenocarcinoma 65 | 1,271
medulloblastoma 62 | 1,524
pituitary cancer 62 | 1,972
posterior fossa group A ependymoma 61 | 1,511
group 3 medulloblastoma 60 | 2,254
adrenocortical carcinoma 59 | 1,427
dermatomyositis 58 | 933
sonic hedgehog group medulloblastoma 56 | 1,482
colon cancer 55 | 1,475
spina bifida 54 | 1,064
cystic fibrosis 53 | 1,665
Rheumatoid Arthritis 51 | 1,160
posterior fossa group B ependymoma 50 | 1,530
cutaneous lupus erythematosus 44 | 1,056
Waldenstrons macroglobulinemia 43 | 765
Alzheimer's disease 39 | 644
Atopic dermatitis 39 | 944
Neurodegenerative disease 39 | 383
gastric carcinoma 39 | 832
esophageal adenocarcinoma 38 | 737
tuberculosis and treatment for 6 months 37 | 686
non primary Sjogren syndrome sicca 35 | 840
Duchenne muscular dystrophy 34 | 602
primary Sjogren syndrome 33 | 789
IGA Glomerulonephritis 32 | 454
active Crohn's disease 31 | 918
atypical teratoid/rhabdoid tumor 31 | 1,095
hereditary spastic paraplegia 31 | 313
acute myeloid leukemia 30 | 780
aldosterone-producing adenoma 30 | 664
mucosa-associated lymphoid tissue lymphoma 30 | 480
progressive supranuclear palsy 30 | 674
Intellectual disability 28 | 573
nasopharyngeal carcinoma 28 | 1,056
Down syndrome 27 | 548
pancreatic carcinoma 27 | 567
Obesity 26 | 616
autosomal dominant Emery-Dreifuss muscular dystrophy 26 | 499
Kidney disease 25 | 396
Amyotrophic Lateral Sclerosis 24 | 431
hepatocellular carcinoma 24 | 532
Heart disease 23 | 279
Parkinson's disease 23 | 364
Schizophrenia 23 | 501
Neuropathy 22 | 210
Prostatic Neoplasms 22 | 471
Epilepsy 21 | 346
Endometriosis 20 | 535
fibroadenoma 20 | 557
Polycystic Ovary Syndrome 19 | 332
periodontitis 19 | 269
gastric cancer 18 | 430
Becker muscular dystrophy 17 | 187
Gaucher disease type 1 17 | 171
Hermansky-Pudlak syndrome 17 | 43
Hypertensive disease 17 | 193
Vascular disease 17 | 281
inflammatory breast cancer 17 | 404
Atherosclerosis 16 | 275
nephrosclerosis 16 | 329

Tissue

Digestive Tract 683 | 18,473
Female tissues 683 | 18,647
Urinary Tract 683 | 18,444
Blood and immune system 682 | 17,995
Liver and Pancreas 681 | 18,136
Endocrine System 680 | 18,512
Nervous System 680 | 18,561
Skin and soft tissues 680 | 18,115
Cardiovascular System 678 | 17,958
Respiratory system 677 | 17,484
Male tissues 675 | 17,969

Target Family

Non-IDG 573 | 11,971
Enzyme 103 | 4,146
Kinase 16 | 634
GPCR 6 | 406
Transporter 3 | 473
Ion Channel 2 | 341
Transcription Factor 2 | 1,400

Reactome Pathway

Vesicle-mediated transport 705 | 705
Signal Transduction 2,516 | 2,516
Immune System 2,184 | 2,184
Metabolism 2,132 | 2,132
Gene Expression 1,755 | 1,755
Metabolism of proteins 1,545 | 1,545
Innate Immune System 1,376 | 1,376
Signaling by GPCR 1,330 | 1,330
Developmental Biology 1,029 | 1,029
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,005 | 1,005
Adaptive Immune System 939 | 939
Disease 856 | 856
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 804 | 804
Metabolism of lipids and lipop... 797 | 797
Hemostasis 669 | 669
Transmembrane transport of sma... 669 | 669
Membrane Trafficking 608 | 608
Cell Cycle 573 | 573
Axon guidance 542 | 542
Neutrophil degranulation 542 | 542
Signaling by Interleukins 501 | 501
Cell Cycle, Mitotic 471 | 471
Signalling by NGF 468 | 468
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 436 | 436
Class I MHC mediated antigen p... 431 | 431
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 424 | 424
Cellular responses to stress 416 | 416
DAP12 interactions 410 | 410
Infectious disease 392 | 392
NGF signalling via TRKA from t... 379 | 379
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 368 | 368
Diseases of signal transductio... 360 | 360
Signaling by EGFR 356 | 356
Transcriptional Regulation by ... 356 | 356
Metabolism of amino acids and ... 354 | 354
DAP12 signaling 347 | 347
Downstream signal transduction 344 | 344
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 330 | 330
Signaling by SCF-KIT 328 | 328
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 322 | 322
FCERI mediated MAPK activation 317 | 317
Signaling by Insulin receptor 313 | 313
Antigen processing: Ubiquitina... 302 | 302
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 291 | 291
Signaling by Wnt 291 | 291
IGF1R signaling cascade 290 | 290
IRS-related events triggered b... 290 | 290
Insulin receptor signalling ca... 289 | 289
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 286 | 286
MAPK family signaling cascades 284 | 284
Signaling by the B Cell Recept... 283 | 283
Asparagine N-linked glycosylat... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 278 | 278
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 269 | 269
M Phase 267 | 267
Interleukin-3, 5 and GM-CSF si... 263 | 263
RET signaling 262 | 262
Signalling to ERKs 255 | 255
Interleukin-2 signaling 254 | 254
Immunoregulatory interactions ... 252 | 252
VEGFR2 mediated cell prolifera... 250 | 250
RHO GTPase Effectors 249 | 249
Signalling to RAS 248 | 248
Interleukin receptor SHC signa... 247 | 247
G alpha (i) signalling events 245 | 245
Signaling by Leptin 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Prolonged ERK activation event... 244 | 244
MAPK1/MAPK3 signaling 243 | 243
Frs2-mediated activation 242 | 242
HIV Infection 242 | 242
ARMS-mediated activation 241 | 241
Signalling to p38 via RIT and ... 241 | 241
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 237 | 237
RAF/MAP kinase cascade 237 | 237
SHC1 events in EGFR signaling 237 | 237
SOS-mediated signalling 237 | 237
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Ub-specific processing proteas... 203 | 203

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Immunoglobulin kappa variable 3-11 IGKV3-11 Tdark Non-IDG 0.00000 0
Apolipoprotein E APOE Tbio Non-IDG -4.17470 15380.4 788
Endoplasmin HSP90B1 Tchem Non-IDG -2.72785 604.5 748
Charged multivesicular body protein 2b CHMP2B Tbio Non-IDG -1.65708 53.0 166
Kinesin-like protein KIF1C KIF1C Tbio Non-IDG -1.21884 20.0 95
Solute carrier family 2, facilitated glucose transporter member 4 SLC2A4 Tchem Transporter -3.30074 2066.8 474
Vesicular integral-membrane protein VIP36 LMAN2 Tbio Non-IDG -1.35463 24.9 101
Tether containing UBX domain for GLUT4 ASPSCR1 Tbio Non-IDG -3.18322 1605.1 195
Exocyst complex component 7 EXOC7 Tbio Non-IDG -1.72231 55.8 158
Apolipoprotein A-I APOA1 Tchem Non-IDG -3.60439 3516.7 901